Futibatinib with PD-1 antibody-based SOC patients with solid tumors

A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid Tumors

Disease Types: Gastrointestinal, Pancreatic, Solid Tumors

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid Tumors 

For More Information:

https://clinicaltrials.gov/study/NCT05945823?term=A%20Phase%202%20Study%20of%20Futibatinib%20in%20Combination%20with%20PD-1%20Antibody-based%20Standard%20of%20Care%20Therapy%20in%20Patients%20with%20Solid%20Tumors%20&rank=1